Avid Bioservices Inc (CDMO)

[MobyInvestor]

Peregrine has most of the P2 cancer data now, and has shared it with FDA. It must be very strong data. The company and FDA seem to have agreed on a P2 trial that will, if consistent with previous results, lead to accelerated bavituximab approval for second-line NSC Lung Cancer. The company (Avid) has already stockpiled large quantities of bavi.

...

I believe bavi will be approved to treat cancer in calendar year 2011.

So, you and a few others here were able to come to that conclusion while legions of well-funded institutions and biotechnology analysts, every single one of them, couldn't?

Right...

Regards,

moby